Vorinostat is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vorinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vorinostat is a anticancer agent. it is formulated as hard gelatin capsules for oral route of administration. It is indicated for for the treatment of newly diagnosed glioblastoma and gliosarcoma, refractory/relapsed follicular lymphoma, diffuse large B-cell lymphoma, B-cell non-Hodgkin lymphoma, mantle cell lymphoma, indolent lymphoma, non-small cell lung cancer, soft tissue sarcoma and metastatic uveal melanoma.
Vorinostat is under development for the treatment of metastatic squamous cell carcinoma of vulvar cancer, penile cancer, cervix cancer, head and neck squamous cell carcinoma anal cancer, newly diagnosed glioblastoma and gliosarcoma, refractory/relapsed follicular lymphoma, diffuse large B-cell lymphoma (first-line), B-cell non-Hodgkin lymphoma, mantle cell lymphoma, indolent lymphoma, non-small cell lung cancer (third line). It was also under development for Niemann-Pick type-C, cutaneous T-cell lymphoma, metastatic colorectal cancer, pancreatic cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, malignant pleural mesothelioma, non-small cell lung cancer (first line), refractory/relapsed multiple myeloma, prostate cancer, small-cell lung cancer (First Line Therapy), metastatic breast cancer, myelodysplastic syndrome, recurrent glioblastoma multiforme, malignant glioma, metastatic clear cell renal cell carcinoma, metastatic, refractory/relapsed acute myeloid leukemia, soft tissue sarcoma and metastatic uveal melanoma.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Vorinostat’s drug-specific PTSR and LoA scores, buy the report here.